Literature DB >> 31911433

Cracking the context-specific PI3K signaling code.

Ralitsa R Madsen1, Bart Vanhaesebroeck1.   

Abstract

Specificity in signal transduction is determined by the ability of cells to "encode" and subsequently "decode" different environmental signals. Akin to computer software, this "signaling code" governs context-dependent execution of cellular programs through modulation of signaling dynamics and can be corrupted by disease-causing mutations. Class IA phosphoinositide 3-kinase (PI3K) signaling is critical for normal growth and development and is dysregulated in human disorders such as benign overgrowth syndromes, cancer, primary immune deficiency, and metabolic syndrome. Despite decades of PI3K research, understanding of context-dependent regulation of the PI3K pathway and of the underlying signaling code remains rudimentary. Here, we review current knowledge on context-specific PI3K signaling and how technological advances now make it possible to move from a qualitative to quantitative understanding of this pathway. Insight into how cellular PI3K signaling is encoded or decoded may open new avenues for rational pharmacological targeting of PI3K-associated diseases. The principles of PI3K context-dependent signal encoding and decoding described here are likely applicable to most, if not all, major cell signaling pathways.
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31911433     DOI: 10.1126/scisignal.aay2940

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  13 in total

Review 1.  At a crossroads: how to translate the roles of PI3K in oncogenic and metabolic signalling into improvements in cancer therapy.

Authors:  Neil Vasan; Lewis C Cantley
Journal:  Nat Rev Clin Oncol       Date:  2022-04-28       Impact factor: 65.011

2.  RNA interference screens discover proteases as synthetic lethal partners of PI3K inhibition in breast cancer cells.

Authors:  Lena Hölzen; Jan Mitschke; Claudia Schönichen; Maria Elena Hess; Sophia Ehrenfeld; Melanie Boerries; Cornelius Miething; Tilman Brummer; Thomas Reinheckel
Journal:  Theranostics       Date:  2022-05-16       Impact factor: 11.600

3.  Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors.

Authors:  Zied Gaieb; Kaelin D Fleming; Manoj K Rathinaswamy; Chiara Borsari; Noah J Harris; Brandon E Moeller; Matthias P Wymann; Rommie E Amaro; John E Burke
Journal:  Elife       Date:  2021-03-04       Impact factor: 8.140

4.  The G-Protein Rab5A Activates VPS34 Complex II, a Class III PI3K, by a Dual Regulatory Mechanism.

Authors:  Thomas C Buckles; Yohei Ohashi; Shirley Tremel; Stephen H McLaughlin; Els Pardon; Jan Steyaert; Moshe T Gordon; Roger L Williams; Joseph J Falke
Journal:  Biophys J       Date:  2020-10-31       Impact factor: 4.033

Review 5.  PI3K in stemness regulation: from development to cancer.

Authors:  Ralitsa R Madsen
Journal:  Biochem Soc Trans       Date:  2020-02-28       Impact factor: 5.407

Review 6.  The Function of NM23-H1/NME1 and Its Homologs in Major Processes Linked to Metastasis.

Authors:  Barbara Mátyási; Zsolt Farkas; László Kopper; Anna Sebestyén; Mathieu Boissan; Anil Mehta; Krisztina Takács-Vellai
Journal:  Pathol Oncol Res       Date:  2020-01-28       Impact factor: 3.201

Review 7.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

8.  Melatonin Induces Melanogenesis in Human SK-MEL-1 Melanoma Cells Involving Glycogen Synthase Kinase-3 and Reactive Oxygen Species.

Authors:  Juan Perdomo; Carlos Quintana; Ignacio González; Inmaculada Hernández; Sara Rubio; Juan F Loro; Russel J Reiter; Francisco Estévez; José Quintana
Journal:  Int J Mol Sci       Date:  2020-07-14       Impact factor: 5.923

Review 9.  Diabetes and susceptibility to infections: Implication for COVID-19.

Authors:  Gustav van Niekerk; Michelle van der Merwe; Anna-Mart Engelbrecht
Journal:  Immunology       Date:  2021-06-24       Impact factor: 7.215

Review 10.  The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-27       Impact factor: 2.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.